TherapeuticsMD, Inc. (TXMD) |
| 2.05 0.06 (2.93%) 04-14 10:48 |
| Open: | 2.03 |
| High: | 2.2047 |
| Low: | 2.02 |
| Volume: | 7,844 |
| Market Cap: | 24(M) |
| PE Ratio: | -34.17 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.40 |
| Resistance 1: | 2.21 |
| Pivot price: | 2.10 |
| Support 1: | 1.90 |
| Support 2: | 1.58 |
| 52w High: | 2.95 |
| 52w Low: | 0.93 |
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
| EPS | 0.010 |
| Book Value | 2.370 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.242 |
| Profit Margin (%) | 10.80 |
| Operating Margin (%) | -37.76 |
| Return on Assets (ttm) | -2.7 |
| Return on Equity (ttm) | 0.3 |
Fri, 10 Apr 2026
TXMD Should I Buy - Intellectia AI
Mon, 06 Apr 2026
[SCHEDULE 13G] TherapeuticsMD, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Thu, 02 Apr 2026
TherapeuticsMD Explains Brief Delay In Annual Filing - The Globe and Mail
Mon, 30 Mar 2026
TXMD: 2025 saw improved results from royalty revenue, but litigation and liquidity risks threaten viability - TradingView — Track All Markets
Mon, 30 Mar 2026
TXMD: Net loss narrowed and license revenue surged as strategic alternatives are explored - TradingView — Track All Markets
Mon, 30 Mar 2026
TherapeuticsMD cuts annual loss while weighing a sale or merger - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |